Abstract
71 infants with RDS who participated in a randomized double-blind study to evaluate whether E administration could prevent bronchopulmonary dysplasia have been evaluated with indirect ophthalmoscopy and fluorescein angiography of the fundus without knowledge of treatment. Infants received E or the carrier vehicle (P) (0.4 ml/kg, Hoffmann-LaRoche, Inc.) IM at admission to the study and 24, 48 and 168 hrs later; more doses were given twice/week while the infant needed O2. E- and P-treated infants were not significantly different in wt., gest. age, Apgar scores, age at treatment and initial severity of RDS. Mean serum E levels were 0.43 mg% pretreatment and averaged 0.64 mg% and 3.90 mg% in the P-treated and E-treated infants, respectively, during the next 7 days. RLF developed in 16 infants; 3 P-treated and 1 E-treated had Stage II changes, the other 12 only Stage I (Reese classification). None developed severe cicatricial changes and most findings have regressed. Although the sample size is small, E administration during the acute phase of RDS does not appear to prevent the development of the active changes of RLF (X2 ≈ 0.58; df = 1; p ≈ 0.45).
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehrenkranz, R., Puklin, J. & Warshaw, J. 1295 EFFECTIVENESS OF VITAMIN E (E) ADMINISTRATION DURING RESPIRATORY DISTRESS SYNDROME (RDS) IN PREVENTING RETROLENTAL FIBROPLASIA (RLF). Pediatr Res 15 (Suppl 4), 659 (1981). https://doi.org/10.1203/00006450-198104001-01324
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-01324